Hemiparesis after Operation of Astrocytoma Grade II in Adults: Effects of Acupuncture on Sensory-Motor Behavior and Quality of Life

Table 5

EORTC QLQ-C30-BN20 scores in 3 groups at baseline and 8th week.

Questionnaire	Scales/Items	IA + SR group (𝑛=18)		SA + SR group (𝑛=17)		SR group (𝑛=18)		P value (ANOVA)
		Baseline	8th week	Baseline	8th week	Baseline	8th week	Baseline	8th week
QLQ-C30	Function scales
	Physical function	70.78±19.07	34.11±30.36^∗	64.65±25.64	56.76±21.35	60.83±28.45	58.39±20.98		0.008^△
	Role function	41.72±17.76	40.50±17.56	46.12±14.72	44.35±16.44	44.83±15.25	43.94±15.86		0.751
	Emotional function	65.22±15.85	47.72±17.57^∗	64.12±17.48	60.06±15.76	63.78±17.02	60.61±14.39		0.031^△
	Cognitive function	47.78±13.49	23.17±16.26^∗	47.47±18.36	38.41±22.86^∗	49.39±17.36	44.89±26.96		0.017^△
	Social function	60.00±23.21	59.44±23.48	53.47±20.09	53.00±20.62	55.56±16.72	53.50±20.64		0.617
	Global QL	56.78±17.46	78.06±18.68^∗	53.35±15.34	65.35±7.93^∗	50.28±8.16	56.89±11.02^∗		0.000^△
	Symptom scales							𝑃>0.05 for all
	Fatigue	46.94±15.70	25.44±21.56^∗	50.12±20.11	37.06±28.91^∗	51.33±19.16	48.22±23.42		0.029^△
	Nausea/vomiting	22.33±7.67	21.56±8.91	21.71±8.01	20.59±9.13	21.89±7.35	22.06±11.00		0.903
	Pain	38.83±8.07	15.06±13.14^∗	37.94±7.52	22.12±13.17^∗	35.89±9.54	31.72±14.92		0.003^△
	Dyspnea	26.89±16.22	26.06±16.67	34.35±8.25	33.59±9.82	31.72±9.69	30.56±11.73		0.241
	Insomnia	31.06±7.76	13.83±11.97^∗	32.06±6.89	27.76±12.03^∗	29.94±7.55	27.28±13.74		0.002^△
	Anorexia	45.72±12.89	15.72±14.83^∗	46.71±20.39	34.24±27.20^∗	45.94±19.86	41.94±23.73		0.003^△
	Constipation	23.56±8.18	23.11±8.70	25.35±14.06	25.00±14.35	24.39±14.61	24.28±16.53		0.917
	Diarrhea	20.22±7.16	19.78±7.79	21.53±19.48	20.94±19.87	22.06±15.27	21.94±19.80		0.927
	Financial impact	78.11±10.35	64.72±29.70	77.94±10.78	76.65±12.45	77.61±12.25	78.06±10.68		0.095
BN-20	Scales
	Future uncertainty	51.06±32.45	32.22±19.77^∗	43.88±31.98	28.94±22.24	45.56±30.26	30.39±21.28		0.899
	Visual disorder	18.83±20.71	17.17±20.81	21.12±21.66	18.76±20.10	21.17±19.71	19.28±19.33		0.948
	Motor dysfunction	68.56±16.48	32.94±18.61^∗	64.12±17.48	54.47±21.14	65.67±16.83	56.72±17.79		0.001^△
	Communication deficit	21.17±23.51	15.06±16.34	17.06±16.98	16.35±16.29	22.06±21.71	21.11±17.94		0.532
	Items							𝑃>0.05 for all
	Headaches	17.28±24.76	13.06±19.88	14.35±21.75	14.06±20.24	14.61±20.76	14.50±19.62		0.975
	Seizures	12.06±15.19	11.17±12.90	10.71±15.30	11.65±15.15	12.56±17.20	11.94±14.75		0.987
	Drowsiness	33.22±13.99	14.44±11.75^∗	37.71±19.94	24.29±11.55^∗	36.50±20.01	28.61±10.37		0.001^△
	Bothered by hair loss	9.39±7.67	9.33±7.59	9.29±7.90	10.24±7.77	8.89±7.81	8.83±7.34		0.858
	Bothered by itchy skin	10.44±11.76	10.39±11.54	9.94±12.22	10.29±12.11	10.28±11.90	11.17±12.42		0.972
	Weakness of both legs	64.78±15.58	32.67±13.46^∗	56.12±24.07	47.71±22.61	60.17±19.19	50.67±21.97		0.019^△
	Trouble controlling bladder	18.11±24.75	11.67±19.01	12.06±18.20	13.82±20.41	18.39±20.04	17.72±19.37		0.646

* 𝑃<0.05, compared with pretreatment in each group by paired t-test, ^△𝑃<0.05, comparison between the three groups by ANOVA. The numbers are the means ± standard deviation.